ibandronate [Bondronat]
Drug6mg iv on days 1-3
NCT Number: NCT00502736
This single arm study will assess the efficacy and safety of loading doses of intravenous Bondronat in patients with breast cancer and malignant bone disease experiencing moderate to severe bone pain. Patients will receive an intravenous infusion of 6mg Bondronat on days 1, 2 and 3. The anticipated time on study treatment is 3 months, and the target sample size is <100 individuals.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Phase 2
Ankara, Turkey (Türkiye)
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
6mg iv on days 1-3
Time frame: Days 1, 7 and 14
Time frame: Days 1, 4 and 7
Time frame: Days 1, 4 and 7
Time frame: Day 7
Hoffmann-La Roche
Industry
An Open Label Study to Assess the Effect of Intravenous Loading Doses of Bondronat on Bone Pain in Patients With Breast Cancer and Skeletal Metastases
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02564107
Bone Diseases, Bone Neoplasms
Plovdiv, Bulgaria
View Trial DetailsNCT02561039
Bone Diseases, Bone Neoplasms
Burgas, Bulgaria
View Trial DetailsNCT02716792
Bone Diseases, Bone Neoplasms
Amboise, France
View Trial DetailsNCT02553707
Bone Diseases, Bone Neoplasms
Budapest, Hungary
View Trial Details